A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus

ISSN： 0114-5916

Source： Drug Safety, Vol.20, Iss.6, 1999-06, pp. : 489-503

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

By Gallwitz Baptist

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 87-100

Adis International

Access to resources Recommend Favorite

Hormone Replacement Therapy in Postmenopausal Women With Diabetes Mellitus: A Risk-Benefit Assessment

By Andersson B.

Drugs & Aging, Vol. 17, Iss. 5, 2000-11 ,pp. : 399-410

Adis International

Access to resources Recommend Favorite

Metformin may reduce the risk of cancer in patients with type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Sitagliptin/Metformin Fixed-Dose Combination: In Patients with Type 2 Diabetes Mellitus

By Chwieduk Claudine M.

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 349-361

Adis International

Access to resources Recommend Favorite

Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth Mary Stein Stephanie Aleskow Davis Stephen N

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 17, 2012-12 ,pp. : 2545-2554

Informa Healthcare

Access to resources Recommend Favorite